Gastrostomy versus nasogastric tube feeding for chemoradiation patients with head and neck cancer: the TUBE pilot RCT

Vinidh Paleri,1,2,3* Joanne Patterson,4 Nikki Rousseau,4 Eoin Moloney,4 Dawn Craig,4 Dimitrios Tzelis,4 Nina Wilkinson,5 Jeremy Franks,4 Ann Marie Hynes,6 Ben Heaven,4 David Hamilton,4 Teresa Guerrero-Urbano,7 Rachael Donnelly,7 Stewart Barclay,8 Tim Rapley4 and Deborah Stocken5,9

1Head and Neck Unit, The Royal Marsden Hospital, London, UK
2Division of Clinical Studies, Institute of Cancer Research, London, UK
3Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
4Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK
5Biostatistics Research group, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK
6Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK
7Department of Radiation Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
8Department of Restorative Dentistry, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
9Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK

*Corresponding author vinidh.paleri@rmh.nhs.uk

Declared competing interests of authors: Vinidh Paleri is a member of the National Institute for Health Research (NIHR) Health Technology Assessment programme Interventional Procedures Panel, and has received travel expenses to disseminate the trial results, as well as expenses from DP Medical Systems (Chessington, UK) and Merck & Co., Inc. (Kenilworth, NJ, USA); the expenses paid by Merck & Co., Inc., include fees to speak at a meeting. Nikki Rousseau and Tim Rapley report grants from NIHR during the conduct of the study.

Disclaimer: This report contains transcripts of interviews conducted in the course of the research and contains language that may offend some readers.

Published April 2018
DOI: 10.3310/hta22160
Scientific summary

Gastrostomy versus nasogastric tube feeding: the TUBE pilot RCT
Health Technology Assessment 2018; Vol. 22: No. 16
DOI: 10.3310/hta22160

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Each year the NHS treats 9000 new patients with head and neck squamous cell cancers (HNSCCs). Stage III and IV HNSCC can be treated non-surgically by chemoradiation therapy (CRT). This treatment offers an overall 60% chance of cure, but at the cost of significant side effects, which have an impact on basic functions of eating, drinking, communication and breathing. Eating and drinking problems are a top concern for HNSCC survivors. Specifically, CRT leads to loss of taste, dry mouth, pain on swallowing and difficulties with swallowing mechanics secondary to fibrosis, which can result in decreased efficiency and a high risk of aspiration of material. A small proportion of patients may never eat or drink again following treatment. Recent work has shown that aspiration pneumonia is responsible for 19% of non-cancer-related deaths in HNSCC at 5 years post treatment.

Over 90% of patients undergoing this treatment require nutritional support to prevent substantial weight loss during and after CRT. There are two options for nutritional support: (1) to have a gastrostomy tube placed prior to the onset of CRT and for patients to start feeding when their nutritional intake becomes compromised; or (2) to have a nasogastric tube fitted, if and when it becomes necessary, as advised by clinical staff. There is no agreed practice across the UK and no national guidelines, with each centre adopting its own practice in accordance with local policies.

Each feeding method has advantages and disadvantages. Nasogastric tube feeding has lower rates of morbidity associated with placement of the tube than gastrostomy tube feeding alone. However, the former is associated with a greater negative effect on body image, is considered more inconvenient and uncomfortable for patients and requires patients to be hospitalised during treatment. Feeding via gastrostomy tube is faster, but it requires a pre-CRT hospital admission and is costlier than a nasogastric tube. Gastrostomy feeding has been identified as a predictor of poorer diet scores at 1 year and of late-onset dysphagia following radiotherapy. This is thought to be because the duration of dependency on alternative feeding is longer than is required for nasogastric tube feeding, giving rise to ‘disuse atrophy’ and, thus, a dysfunctional swallowing mechanism. Systematic reviews have highlighted the lack of evidence regarding the impact of a gastrostomy on swallowing outcomes, which has resulted from methodological flaws and significant selection bias. One randomised controlled study (RCT) from Australia aimed to address this question, but the study closed early, as the number of patients recruited was insufficient. Limited information was available on the problems associated with recruitment. Findings on which feeding tube route resulted in better swallowing outcomes were inconclusive.

The purpose of this study was to explore the feasibility of conducting a RCT comparing the two feeding tube options, with particular emphasis on patient willingness to be randomised and clinician willingness to approach eligible patients.

Aim and objectives

Our aim was to determine whether or not a definitive RCT of head and neck cancer patients with minimal swallowing problems undergoing CRT comparing prophylactic gastrostomy tube feeding with oral feeding plus as-needed nasogastric tube feeding was feasible (the TUBE trial). The TUBE trial feasibility phase is a necessary prelude to a full trial of these complex interventions, to assess whether or not an adequate proportion of eligible patients can be recruited into the trial, according to both quantitative and qualitative data parameters.
The objectives were to:

1. identify recruitment and retention rates and explore barriers to, and facilitators of, trial implementation and reasons for attrition
2. carry out a preliminary estimation of key parameters to inform design and study processes
   - i. refine power/sample size for the definitive trial primary outcome
   - ii. test subsidiary quality-of-life outcomes
   - iii. monitor nutritional parameters
3. provide preliminary health economics metrics
   - i. assess the economic value of information derived from the feasibility study
   - ii. provide a preliminary estimate of the costs, effects and relative cost-effectiveness.

**Methods/design**

This was a mixed-methods multicentre study to establish the feasibility of a RCT comparing oral feeding plus pre-treatment gastrostomy with oral feeding plus as-required nasogastric tube feeding in patients with HNSCC.

We aimed to randomise 60 participants to the two arms of the study (using a 1 : 1 ratio). The eligibility criteria were patients with advanced-staged HNSCC who were suitable for primary CRT with curative intent and who presented with no swallowing problems.

The primary outcome was the willingness to be randomised and recruited to the trial. A qualitative process evaluation investigating patient, family and friends and staff experiences of trial participation was conducted. Patient interviews were conducted within 2 weeks of recruitment discussions. The focus of these interviews was on the patients’ experiences and understanding of trial processes and the intervention (i.e. feeding tube options). When possible, follow-up interviews were conducted approximately 8 months after recruitment to explore the acceptability of assessment tools and patients’ experiences of the intervention.

Clinicians (medical, nursing, dietetic and speech and language specialists) were interviewed to allow us to understand and map existing processes of care in relation to tube feeding in this patient group, and to explore experiences of, and perspectives on, the TUBE trial and the study interventions.

Baseline data included patient demographics, disease characteristics and the treatment plan. Questionnaires included the MD Anderson Dysphagia Inventory, the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire – C30 (EORTC QLQ-C30), the EORTC QLQ – Module for Head and Neck Cancer (EORTC QLQ-H&N35) and the Short Form questionnaire-36 items. Clinical assessments included body mass index and usual weight, Performance Status Scale (normalcy of diet subscale) and data from oral health assessment. Questionnaires and assessments were collected again at 3 months, 6 months and 12 months.

A within-trial economic evaluation was conducted. Data on the use of hospital and primary care services and patient/family/carer costs were collected. A bespoke decision-analytic economic model was also developed to estimate the costs, effects and relative cost-effectiveness of the two feeding tube options. The clinical pathways of patients within the feasibility study were used to help inform the model structure. An economic value-of-information analysis was performed to identify if further research would be cost-effective.
Results

The trial was conducted across five head and neck cancer centres, with the period of recruitment ranging from 3 to 11 months. In total, 75 patients were identified as fitting the eligibility criteria, of whom 17 agreed to being randomised [0.23, 95% confidence interval (CI) 0.13 to 0.32]. Retention rates were high at completion of treatment (0.94, 95% CI 0.83 to 1.05). Data completeness was excellent.

The qualitative substudy identified a collection of factors that had an impact on recruitment to the trial, many of which were potentially amenable to change. Clinical and organisational contexts were critical to the implementation of the TUBE trial. Variation in clinician preferences and practices was apparent. Operational contexts concerning the set-up and conduct were identified as extrinsic factors that had an impact on the study. The eligibility criteria and the interpretation of these were seen as potential barriers. Integrating research and clinical pathways required additional work. There was over-riding support for identifying best practice for feeding tube selection.

A key issue explaining the differential recruitment between sites was the degree to which the whole multidisciplinary team gave a consistent demonstration of equipoise at all patient interactions at which supplementary feeding was discussed. Patients described their decision-making regarding randomisation. Some had strong preferences, whereas others were ambivalent over feeding tube selection. There were concerns regarding whether or not participation in the TUBE trial could affect the timing of the patients’ care pathways in the lead-up to treatment. The importance of feeding tube placement and its perceived problems became more obvious to patients during and after CRT. Patients described managing their feeding tube. Patients with a nasogastric tube reported its insertion as being very unpleasant, and there were concerns over dislodgement.

The economic model, based on published evidence and expert opinion, suggests that pre-treatment gastrostomy tube feeding is not a cost-effective option over a 6-month time horizon. However, more work is required to substantiate this finding. The economic value-of-information analysis indicates that conducting additional research to eliminate uncertainty around all model parameters is highly likely to be cost-effective.

Conclusions

The TUBE trial identified a range of issues that affected recruitment to the feasibility of randomising patients with HNSCC being treated with CRT to either pre-treatment gastrostomy or reactive nasogastric tube placement. Our process evaluation identified organisational and operational issues that need to be overcome to improve recruitment for such a trial, when multiple professionals have a stake in deciding recruitment, driven by clinical experience and personal views. At least one-third of patients could be recruited to a future trial to address this important treatment decision if appropriate measures are implemented to address these issues. The health economic argument is reasonably compelling to warrant the need for a further study, the design for which will need to take into consideration the results from the TUBE trial.

Trial registration

This trial is registered as ISRCTN48569216.
Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.

‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: [http://www.nets.nihr.ac.uk/programmes/hta](http://www.nets.nihr.ac.uk/programmes/hta)

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 12/35/32. The contractual start date was in January 2014. The draft report began editorial review in July 2016 and was accepted for publication in July 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2018. This work was produced by Paleri et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Health Technology Assessment Editor-in-Chief

Professor Hywel Williams  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Director of the NIHR Dissemination Centre, University of Southampton, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk